ELTROMBOPAG

SynDRA canonical compound SYN0011973 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	CYP2C8 \| MPL
Mechanism of action	thrombopoietin receptor agonist
Indication	anemia \| anemia, hepatitis c, thrombocytopenia \| hepatitis C \| thrombocytopenia
Disease area	hematology \| hematology \| hematology, infectious disease \| infectious disease

All known targets

MPL
ABCG2
CYP2C8
KCNH2

Mechanisms of action (all sources)

thrombopoietin receptor agonist
MPL AGONIST

Drug classes

Thrombopoietin Receptor Agonists
Thrombopoietin Receptor Agonist
Organic Anion Transporting Polypeptide 1B1 Inhibitors
Breast Cancer Resistance Protein Inhibitors
UGT1A1 Inhibitors
UGT2B7 Inhibitors
UGT2B15 Inhibitors
UGT1A3 Inhibitors
UGT1A4 Inhibitors
UGT1A6 Inhibitors
UGT1A9 Inhibitors
Antineoplastic Agents

ATC classes

B02B · VITAMIN K AND OTHER HEMOSTATICS

Cross-references

PubChem CID: 135449332
ChEMBL: CHEMBL461101
DrugBank: DB06210
ChEBI: 85010
KEGG: D03978
RxNorm: 40048
PDB: ZPS
Wikipedia: Eltrombopag
TTD: D00PEH
LINCS BRD: BRD-K11626735

Synonyms

SB 497115
revolade
eltrombopag olamine
ppromacta
SB497115
Revolade
Eltrombopag [INN]
SB-497115
[1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2Z)-[1-(3,4-dime
Thylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-(9CI)
(E)-3\'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2\'-hydroxybiphenyl-3-carboxylic acid
(Z)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
UNII-S56D65XJ9G
(ZE)-Eltrombopag
Eltrombopag free base
CHEMBL461101
S56D65XJ9G
3'-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
CHEBI:85010
Eltrombopag (SB-497115-GR)
496775-61-2 (free base)
NCGC00274067-01
(1,1'-Biphenyl)-3-carboxylic acid, 3'-((2Z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-
(Z)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,
3'-{2-[(4E)-1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid
AMG531
HSDB 8212
3'-((2Z)-2-(1-(3,4-DIMETHYLPHENYL)-3-METHYL-5-OXO-1,5-DIHYDRO-4H-PYRAZOL-4-YLIDENE)DIAZANYL)-2'-HYDROXYBIPHENYL-3-CARBOXYLIC ACID
3'-{(2z)-2-(1-[3,4-dimethylphenyl]-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene)diazanyl}-2'-hydroxybiphenyl-3-carboxylic acid
Eltrombopag- Bio-X
ELTROMBOPAG [MI]
SB-497 115
ELTROMBOPAG [VANDF]
ELTROMBOPAG [MART.]
SCHEMBL18910
ELTROMBOPAG [WHO-DD]
MLS006010024
SCHEMBL164270

Reported adverse events

Arthralgia
Asthenia
Back pain
Blood bilirubin increased
Cataract
Cough
Dizziness
Fatigue
Headache
Hepatotoxicity
Myalgia
Nasopharyngitis

Look up ELTROMBOPAG in the interactive SynDRA portal →